Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7OKQV)

Drug Name
Cholic Acid Drug Info
Synonyms
cholic acid; 81-25-4; Cholalic acid; cholate; Cholalin; Colalin; Cholsaeure; NSC-6135; Cholic acid, 5beta-; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid; 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oic acid; UNII-G1JO7801AE; HSDB 982; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; Cholic acid [USAN]; 3,7,12-Trihydroxycholanic acid; G1JO7801AE; CHEMBL205596; CHEBI:16359; NSC6135; BHQCQFFYRZLCQQ-OELDTZBJSA-N
Cross-matching ID
PubChem CID
221493
ChEBI ID
CHEMBL205596
CAS Number
CAS 81-25-4
TTD Drug ID
D0OR2L
VARIDT Drug ID
DR00657
INTEDE Drug ID
DR0314
ACDINA Drug ID
D00943

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 1.92 4.18e-2 48/60 (80%) MT1HL1;MT1E;MT1H;...
Oxidative phosphorylation 1.86 4.18e-2 93/133 (69.92%) SDHD;ATP5MC2;COX7B;...
Insulin signaling pathway -1.68 4.92e-2 121/137 (88.32%) PHKB;INS;MAPK10;...
Intestinal immune network for IgA production -1.70 4.12e-2 38/48 (79.17%) HLA-DOB;IL15RA;IL5;...
Adipocytokine signaling pathway -1.76 2.83e-2 64/69 (92.75%) MAPK10;NFKBIB;G6PC3;...
N-Glycan biosynthesis -1.76 3.04e-2 38/50 (76%) ALG8;MGAT1;ALG3;...
Central carbon metabolism in cancer -1.77 2.85e-2 67/70 (95.71%) PDHA1;SLC16A3;HK2;...
Graft-versus-host disease -1.79 2.40e-2 32/42 (76.19%) HLA-DOB;HLA-E;HLA-G;...
Synaptic vesicle cycle -1.81 2.37e-2 63/78 (80.77%) DNM2;ATP6V1D;SLC6A9;...
Glycerophospholipid metabolism -1.85 1.78e-2 71/98 (72.45%) PLA2G6;PLPP1;LPIN1;...
Viral myocarditis -1.86 1.68e-2 53/60 (88.33%) CASP9;HLA-DOB;HLA-E;...
Steroid biosynthesis -1.90 1.03e-2 19/20 (95%) CYP51A1;SOAT2;SC5D;...
Autoimmune thyroid disease -2.03 0.00e+0 46/53 (86.79%) HLA-DOB;HLA-E;HLA-G;...
Asthma -2.03 0.00e+0 25/31 (80.65%) IL13;FCER1A;PRG2;...
Type II diabetes mellitus -2.04 0.00e+0 42/46 (91.3%) PRKCD;INS;MAPK10;...
Ether lipid metabolism -2.05 0.00e+0 32/49 (65.31%) PLA2G6;PLPP1;PLPP3;...
Systemic lupus erythematosus -2.06 0.00e+0 45/135 (33.33%) HLA-DPA1;HLA-DOA;HLA-DPB1;...
Allograft rejection -2.07 0.00e+0 32/38 (84.21%) HLA-DOB;HLA-E;HLA-G;...
Regulation of lipolysis in adipocytes -2.11 0.00e+0 52/55 (94.55%) PNPLA2;PIK3CB;NPY;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H